Paper Review — Verify Claims Fast

Concise appraisal

The preprint reports that disease relevant tau fibrils (PHF and CTE folds produced from tau297-391) catalyze Aβ42 primary nucleation in a fold dependent, enzyme like manner (CTE>PHF), altering Aβ42 kinetics, fibril polymorphism and increasing biological toxicity in cells and C elegans Tau catalyzes Aβ42 aggregation (preprint)

Detailed critical review and analysis

What the paper claims (core findings)

• Tau fibrils mimicking PHF and CTE folds catalyze heterotypic Aβ42 primary nucleation and change aggregation kinetics consistent with an enzyme-like, saturable process; CTE seeds show higher catalytic efficiency than PHF seeds Kinetic evidence for tau catalytic activity
• Docking and structural comparison identify a tau surface (residues ~351–379, docking focus 353–369) exposed more in the CTE fold and less accessible in PHF, proposed as the catalytic pocket binding Aβ42 core segments (e.g., KLVFFA) Docking identifies tau residues 353-369 pocket
• Cross-seeding changes Aβ42 fibril morphology: CTE seeds produced a narrower crossover distribution (centered ~66 nm) versus broader polymorphism for PHF or unseeded Aβ42; tau seeds also reduce fibril length consistent with faster nucleation CTE seeds constrain Aβ42 polymorphism
• Biological readouts: coadministration of tau seeds with Aβ42 increases cytotoxicity in SH-SY5Y cells and worsens motility in Aβ42-expressing C elegans; effects are stronger with CTE seeds and show apparent synergy beyond additive expectation Increased toxicity with tau seeds

Why this is interesting biologically

The paper addresses a key unanswered mechanistic question in multi proteinopathies: can preformed disease-specific amyloid surfaces act as selective catalytic platforms for heterotypic primary nucleation of a different amyloidogenic protein, and does amyloid fold (polymorph) determine reactivity? The authors supply kinetic analyses, structural docking, TEM morphological evidence, IP co-precipitation, and biological toxicity assays to support a model in which specific tau folds (CTE>PHF) template and catalyze Aβ42 nucleation and shape its polymorphic outcome Overall mechanistic claim

Critical evaluation and limitations

1. Use of truncated tau fragment: Seeds were produced from tau(297-391) per established methods to reproduce PHF/CTE folds, which is a well-justified experimental choice for structural control but may not fully capture contributions of full-length tau (N and C terminal domains, post-translational modifications) present in disease brains. The authors acknowledge this limitation and the need to test brain derived full-length seeds Truncated tau fragment caveat
2. In vitro environment vs brain milieu: ThT assays, quiescent incubations, docking and sonicated seeds are standard and powerful, but lack cellular chaperones, lipids, extracellular matrix, proteases, and clearance pathways that can alter nucleation and templating. Toxicity assays in SH-SY5Y and C elegans are supportive but limited in mammalian physiological complexity Model limitations acknowledged
3. Docking is predictive, not definitive: HPEPDOCK/MOPEP docking indicates favorable poses and a candidate pocket (353–369) but lacks experimental high-resolution validation (e.g., cryoEM of a tau–Aβ complex or mutational scanning of tau seed residues to show loss/gain of catalysis). The docking conclusion is plausible but requires orthogonal structural validation In silico docking details
4. Data availability and reproducibility: The manuscript does not provide centralized raw data accession numbers or seed sequences beyond the fragment; the Methods are well detailed but public deposition of raw kinetic traces, TEM images and docking poses would improve reproducibility and independent re-analysis. The authors note data availability is unknown in the record provided Data availability gap
5. Statistical power for biological assays: SH-SY5Y and worm assays are convincing directionally but sample sizes and replication across labs are limited; stronger inference would follow larger n, multiple cell types, human iPSC neurons and mammalian in vivo studies (mouse) including brain-derived tau seeds Biological assay sample size note

Key methodological strengths

• Comprehensive kinetic modeling using AmyloFit and multi-concentration global fits, testing alternative microscopic models and showing best fits for a saturated secondary nucleation model and enzyme-like Hill kinetics for initial rate analyses Robust kinetic modeling
• Multiple orthogonal readouts: ThT kinetics, TEM morphological quantification (crossover distances, length), immunoprecipitation, docking and two biological models (cells and nematodes) increase confidence versus single-assay claims Multiple orthogonal assays

Where the claim could be falsified (useful tests)

1. Use full-length, post-translationally modified, brain derived PHF/CTE tau seeds (from AD and CTE brains) in the same kinetic framework to determine whether fold-dependent catalysis holds with native tau complements.
2. Site-directed mutagenesis or chemical modification of tau residues 353–369 in seed-forming constructs to directly test loss/gain of catalytic activity in cross-seeding kinetics and in cellular toxicity assays.
3. High-resolution structural determination (cryoEM or solid-state NMR) of an Aβ42 monomer/nucleus bound to tau seed surfaces to experimentally define the interface and test docking predictions.
4. Orthogonal in vivo mammalian models (e.g., intracerebral administration of PHF/CTE seeds into Aβ transgenic mice) to test whether tau seed administration accelerates Aβ deposition, changes polymorphism and worsens neuropathology/behavior.

Practical implications and translational perspective

If validated in native full-length tau and mammalian systems, the finding that specific tau folds catalyze Aβ nucleation suggests new therapeutic angles: targeting the catalytic surface on tau (small molecules, antibodies) could reduce heterotypic cross-seeding and downstream synergy between Aβ and tau. The fold-specificity implies that conformation-selective therapeutics might be required rather than generic anti-amyloid agents Therapeutic implication noted

Concrete suggestions to improve the study

1. Deposit raw kinetic traces, TEM micrographs, docking poses and scripts in public repositories (Zenodo, EMPIAR, GitHub) with accession links in the paper to increase reproducibility.
2. Repeat key kinetics with brain-derived full-length PHF and CTE seeds and include human iPSC-derived neurons for toxicity assays.
3. Perform alanine scanning or charge reversals in tau residues 353–369 in seed-competent constructs to test the predicted pocket experimentally.
4. Provide additional negative controls (other disease amyloid polymorphs) and test whether tau-catalysis extends to other amyloid clients beyond Aβ42 (specificity vs promiscuity).

Quick data visualizations (reproduced from the paper excerpts)

Summary conclusion with confidence

Overall, the manuscript presents a strong, multi-assay body of evidence that disease-mimicking tau polymorphs can selectively catalyze Aβ42 primary nucleation in a fold-dependent manner and that CTE-like folds are more catalytic than PHF-like folds; kinetic modeling, TEM and docking are internally consistent and supported by biological readouts. Major open questions are whether full-length, brain-derived tau reproduces the effect, and definitive structural proof of the tau–Aβ interaction site is still needed. Confidence in the core mechanistic claim is moderate-high pending orthogonal validation in mammalian/in situ contexts Paper concluding statement

Further bespoke BGPT quick actions

Author reviews